Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Breast Neoplasms 304Carcinoma, Non-Small-Cell Lung 182Ovarian Neoplasms 154Lung Neoplasms 92Esophageal Neoplasms 75Triple Negative Breast Neoplasms 71Stomach Neoplasms 71Fallopian Tube Neoplasms 68Squamous Cell Carcinoma of Head and Neck 51Esophageal Squamous Cell Carcinoma 50Neoplasm Metastasis 48Neoplasms 45Endometrial Neoplasms 42Head and Neck Neoplasms 41Carcinoma, Ovarian Epithelial 41Uterine Cervical Neoplasms 37Recurrence 26Carcinoma, Squamous Cell 23Adenocarcinoma Of Esophagus 22Urinary Bladder Neoplasms 19Melanoma 19Inflammatory Breast Neoplasms 19Prostatic Neoplasms 18Adenocarcinoma of Lung 17Carcinoma 15Breast Neoplasms, Male 15Unspecified Adult Solid Tumor, Protocol Specific 14Testicular Neoplasms 13Small Cell Lung Carcinoma 12Peritoneal Neoplasms 12

Interventions

olaparib 3Carboplatin 2pembrolizumab 1Trabectedin 1Surveys and Questionnaires 1Secretin 1Paclitaxel 1Genotype 1Genetic Counseling 1Demography 1Data Collection 1Cognitive Behavioral Therapy 1Biopsy, Fine-Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Fanconi Anemia, Complementation Group D1 × Paclitaxel × Clear all
NCT05485766 2025-03-20

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Okayama University

Phase 2 Recruiting
23 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡